{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T23:52:44Z","timestamp":1780789964235,"version":"3.54.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"NIH Office of the Director","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Anaphylaxis represents the most extreme and life-threatening form of allergic disease and is considered a medical emergency requiring immediate intervention. Additionally, some people with mastocytosis experience recurrent episodes of anaphylaxis during normal daily activities without exposure to known triggers. While acute therapy consists primarily of epinephrine and supportive care, chronic therapy relies mostly on desensitization and immunotherapy against the offending allergen, which is a time-consuming and sometimes unsuccessful process. These treatments also necessitate identification of the triggering allergen which is not always possible, and thus highlighting a need for alternative treatments for mast cell-mediated diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The exon-skipping oligonucleotide KitStop was administered to mice intradermally, intraperitoneally, or systemically at a dose of 12.5 mg\/kg. Local mast cell numbers were enumerated via peritoneal lavage or skin histology, and passive systemic anaphylaxis was induced to evaluate KitStop\u2019s global systemic effect. A complete blood count and biochemistry panel were performed to assess the risk of acute toxicity following KitStop administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Here, we report the use of an exon-skipping oligonucleotide, which we have previously termed KitStop, to safely reduce the severity and duration of the anaphylactic response via mast cell depopulation in tissues. KitStop administration results in the integration of a premature stop codon within the mRNA transcript of the KIT receptor\u2014a receptor tyrosine kinase found primarily on mast cells and whose gain-of-function mutation can lead to systemic mastocytosis. Following either local or systemic KitStop treatment, mice had significantly reduced mast cell numbers in the skin and peritoneum. In addition, KitStop-treated mice experienced a significantly diminished anaphylactic response using a model of passive systemic anaphylaxis when compared with control mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>KitStop treatment results in a significant reduction in systemic mast cell responses, thus offering the potential to serve as a powerful additional treatment modality for patients that suffer from anaphylaxis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1006741","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T04:59:07Z","timestamp":1675141147000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The exon-skipping oligonucleotide, KitStop, depletes tissue-resident mast cells in vivo to ameliorate anaphylaxis"],"prefix":"10.3389","volume":"14","author":[{"given":"Barry A.","family":"Hedgespeth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Snider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie J.","family":"Bitting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Cruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: Summary report\u2013second national institute of allergy and infectious Disease\/Food allergy and anaphylaxis network symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.06.031","article-title":"Fatal anaphylaxis: Mortality rate and risk factors","volume":"5","author":"Turner","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.07.040","article-title":"Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, 1993-1994 to 2004-2005","volume":"120","author":"Poulos","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.08.016","article-title":"Anaphylaxis in America: The prevalence and characteristics of anaphylaxis in the united states","volume":"133","author":"Wood","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000354543","article-title":"World allergy organization anaphylaxis guidelines: 2013 update of the evidence base","volume":"162","author":"Simons","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1369\/0022155414545334","article-title":"Mast cell function: A new vision of an old cell","volume":"62","author":"da Silva","year":"2014","journal-title":"J Histochem Cytochem"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.06.012","article-title":"Diagnosis and management of anaphylaxis in precision medicine","volume":"140","author":"Castells","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/all.13319","article-title":"EAACI guidelines on allergen immunotherapy: IgE-mediated food allergy","volume":"73","author":"Pajno","year":"2018","journal-title":"Allergy"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2007.00520.x","article-title":"Mast cells in the promotion and limitation of chronic inflammation","volume":"217","author":"Metz","year":"2007","journal-title":"Immunol Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0631","article-title":"Kit and Fc\u03f5RI mediate unique and convergent signals for release of inflammatory mediators from human mast cells","volume":"104","author":"Hundley","year":"2004","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2012.06.030","article-title":"Targeting c-kit in the therapy of mast cell disorders: Current update","volume":"690","author":"El-Agamy","year":"2012","journal-title":"Eur J Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.125237","article-title":"Concurrent inhibition of kit- and Fc\u03f5RI-mediated signaling: Coordinated suppression of mast cell activation","volume":"324","author":"Jensen","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2014.01.002","article-title":"Functional deregulation of kit: link to mast cell proliferative diseases and other neoplasms","volume":"34","author":"Cruse","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"key":"B14","doi-asserted-by":"publisher","first-page":"E9030","DOI":"10.3390\/ijms21239030","article-title":"Diagnosis, classification and management of mast cell activation syndromes (MCAS) in the era of personalized medicine","volume":"21","author":"Valent","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.023","article-title":"AAAAI mast cell disorders committee work group report: Mast cell activation syndrome (MCAS) diagnosis and management","volume":"144","author":"Weiler","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ymthe.2021.08.009","article-title":"Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasms","volume":"30","author":"Snider","year":"2022","journal-title":"Mol Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3.23.1","DOI":"10.1002\/0471142735.im0323s74","article-title":"Generation, isolation, and maintenance of rodent mast cells and mast cell lines","volume":"74","author":"Jensen","year":"2006","journal-title":"Curr Protoc Immunol"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-62703-496-8_10","article-title":"Protocols for the induction and evaluation of systemic anaphylaxis in mice","volume-title":"Methods Mol Biol","author":"Doyle","year":"2013"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1608520113","article-title":"Exon skipping of Fc\u03f5RI\u03b2 eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy","volume":"113","author":"Cruse","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2015.01.004","article-title":"Idiopathic anaphylaxis","volume":"35","author":"Fenny","year":"2015","journal-title":"Immunol Allergy Clin North Am"},{"key":"B21","article-title":"Pathogenesis, newly recognized etiologies, and management of idiopathic anaphylaxis","volume":"19","author":"Kuhlen","year":"2015","journal-title":"Discov Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13402","article-title":"Idiopathic anaphylaxis","volume":"49","author":"Bil\u00f2","year":"2019","journal-title":"Clin Exp Allergy"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-019-08769-2","article-title":"Mast cell biology at molecular level: a comprehensive review","volume":"58","author":"Elieh Ali Komi","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nature10456","article-title":"Pathogenic exon-trapping by SVA retrotransposon and rescue in fukuyama muscular dystrophy","volume":"478","author":"Taniguchi-Ikeda","year":"2011","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85908","article-title":"Modulation of LMNA splicing as a strategy to treat prelamin a diseases","volume":"126","author":"Lee","year":"2016","journal-title":"J Clin Invest"},{"key":"B26","doi-asserted-by":"publisher","first-page":"106ra107","DOI":"10.1126\/scitranslmed.3002847","article-title":"Splicing-directed therapy in a new mouse model of human accelerated aging","volume":"3","author":"Osorio","year":"2011","journal-title":"Sci Transl Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq731","article-title":"Anti-tumor activity of splice-switching oligonucleotides","volume":"38","author":"Bauman","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1172\/JCI82534","article-title":"Antisense oligonucleotide\u2013mediated MDM4 exon 6 skipping impairs tumor growth","volume":"126","author":"Dewaele","year":"2016","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1108482108","article-title":"Antitumorigenic potential of STAT3 alternative splicing modulation","volume":"108","author":"Zammarchi","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.247","article-title":"Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo","volume":"108","author":"Nielsen","year":"2013","journal-title":"Br J Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/emmm.201202168","article-title":"Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice","volume":"5","author":"Gedicke-Hornung","year":"2013","journal-title":"EMBO Mol Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201505047","article-title":"Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy","volume":"7","author":"Gramlich","year":"2015","journal-title":"EMBO Mol Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann Neurol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70195-4","article-title":"Safety and efficacy of drisapersen for the treatment of duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study","volume":"13","author":"Voit","year":"2014","journal-title":"Lancet Neurol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1177\/0883073815627882","article-title":"Intrathecal injections in children with spinal muscular atrophy","volume":"31","author":"Hach\u00e9","year":"2016","journal-title":"J Child Neurol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002445","article-title":"Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy","volume":"86","author":"Chiriboga","year":"2016","journal-title":"Neurology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1006741\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T04:59:13Z","timestamp":1675141153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1006741\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2023.1006741"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1006741","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,31]]},"article-number":"1006741"}}